Corporate Fact Sheet

CORPORATE FACT SHEET

Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept), its first commercialized product, Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

Marketed Products Regeneron currently markets ARCALYST® (rilonacept) Injection for Subcutaneous Use for the treatment of a rare, inherited, inflammatory condition.

Clinical Product Candidates Senior Regeneron has multiple product candidates in late-stage development programs, including aflibercept Management and VEGF Trap-Eye, which are both being evaluated in Phase 3 trials. Rilonacept (IL-1 Trap) In gout, uric acid crystals stimulate the production of IL-1, which causes an inflammatory response in the joints and surrounding tissues. Rilonacept is an agent that inhibits IL-1. Leonard S. Schleifer, Regeneron has completed a Phase 2 study of rilonacept in the prevention of gout flares in patients initiating M.D., Ph.D. therapy with urate-lowering therapy. Phase 3 clinical studies are in development. President and Chief Aflibercept (VEGF Trap) Vascular endothelial growth factor (VEGF) is secreted by many tumors to Executive Officer stimulate new blood vessels that help grow and support the tumor. Aflibercept is a fully human soluble George D. Yancopoulos, VEGF receptor fusion protein with a unique mechanism-of-action to block VEGF from connecting with its cell surface receptor and stimulating angiogenesis. Aflibercept is a potent angiogenesis inhibitor, which M.D., Ph.D. binds VEGF-A more tightly than monoclonal antibodies, and blocks all VEGF-A isoforms plus placental Executive Vice President, growth factor (PIGF), another angiogenic growth factor that appears to play a role in tumor angiogenesis. Chief Scientific Officer, and President, Regeneron Regeneron and its development partner, sanofi-aventis, are evaluating aflibercept in a broad-based clinical Research Laboratories development program including several Phase 2 and 3 clinical trials in a variety of cancer types for potential indications in Europe, Japan and the United States. In 2007, the companies initiated four Phase 3 trials Murray A. Goldberg evaluating aflibercept in combination with standard chemotherapy regimens in patients with colorectal Senior Vice President, cancer, non-small cell lung cancer (NSCLC), prostate cancer, and pancreatic cancer. The National Cancer Finance and Administration, Institute has initiated 16 additional aflibercept trials. Chief Financial Officer, VEGF Trap-Eye VEGF also promotes abnormal blood vessel growth and fragility in the eye, which can Treasurer, and Assistant lead to the development of several eye diseases, including the neovascular “wet” form of age-related macular Secretary degeneration (wet AMD), a leading cause of blindness in adults. Wet AMD occurs when new blood vessels forming beneath the macula expand and leak fluid that blocks vision. Stuart A. Kolinski Senior Vice President, A Phase 2 study of VEGF Trap-Eye has been completed and two Phase 3 studies are underway in wet AMD. A Phase 1 study of VEGF Trap-Eye in patients with diabetic macular edema (DME), a swelling of the retina in General Counsel, and people with diabetes caused by fluid leaking from blood vessels within the macula, has been completed. A Secretary Phase 2 study in DME is in development. Regeneron has a development collaboration with Bayer HealthCare AG to develop the VEGF Trap-Eye outside the United States. Peter Powchik, M.D. Senior Vice President, REGN88 (IL-6R antibody) Regeneron and it’s development partner, sanofi-aventis, have initiated a Phase Clinical Development 1 trial of REGN88, a human monoclonal antibody to the interleukin-6 receptor, in patients with rheumatoid arthritis. The IL-6R antibody is a therapeutic agent that blocks IL-6, a protein in the body that plays an Neil Stahl, Ph.D. important role in the regulation of inflammatory and immune responses. Senior Vice President, Research and Development PHASE 1 PHASE 2 PHASE 3 Sciences ARCALYST ® (rilonacept) Gout Flare Prevention VEGF Trap-Eye Robert J. Terifay Wet age-related macular degeneration Senior Vice President, Diabetic macular edema Commercial Aﬂibercept (VEGF Trap) 2nd-line metastatic colorectal cancer Daniel Van Plew 1st-line metastatic pancreatic cancer Senior Vice President 2nd-line non-small cell lung cancer and General Manager, 1st-line metastatic prostate cancer Industrial Operations 1st-line metastatic colorectal cancer other studies and Product Supply REGN88 (IL-6R antibody) Rheumatoid arthritis REGN421 (Dll4 antibody) Advanced malignancies

Corporate New Drug Development Technology Platforms Snapshot Regeneron has developed the VelociSuite of technologies, comprising VelociGene®, VelociMouse™, VelocImmune®, and VelociMab™, which increases the efficiency and decreases the time involved in progressing Ticker Symbol from early discovery efforts through drug candidate generation. Together, these technologies allow Regeneron REGN (NASDAQ) scientists to determine the best targets for therapeutic intervention, and then rapidly generate high-quality, fully human antibodies as drug candidates addressing these targets. Corporate Headquarters Perhaps the most powerful pre-existing approach for understanding the function of each gene and its product Regeneron involved generating mice that are either missing a specific gene (a“ knockout”) or contain extra copies of a Pharmaceuticals, Inc. specific gene (a“ transgenic”). Until now, efforts to generate such genetically modified mice were arduous 777 Old Saw Mill River Road and time-consuming. Regeneron scientists developed VelociGene and VelociMouse as powerful new high- Tarrytown, NY 10591 throughput approaches for generating knockout and transgenic mouse models, allowing for the generation Industrial Operations of thousands of such models, which can be used to evaluate each gene of interest. and Product Supply Once a gene has been validated as a target for therapeutic intervention, Regeneron scientists can use the Regeneron VelocImmune and VelociMab technologies to rapidly generate high-quality, fully human antibodies as drug Pharmaceuticals, Inc. candidates addressing these targets. The VelocImmune mice represent a new standard for generating human 81 Columbia Turnpike antibodies. Unlike other human antibody mouse platforms the VelocImmune mouse’s humanized immune Rensselaer, NY 12144 system appears to work as efficiently as that of a normal mouse, except that it allows for the generation of human antibodies. Once VelocImmune mice have been used to generate antibodies, Regeneron scientists Web Site can then utilize the high-throughput VelociMab technology to extract the antibodies from the mice, screen www.regeneron.com for antibodies with the best and most desirable characteristics, and then generate manufacturing cell lines producing high levels of the desired antibodies for clinical development and potential commercial use. Manufacturing Capabilities The Process Development and Industrial Operations and Product Supply groups at Regeneron have substantial experience and expertise in the development and implementation of large-scale (10,000 liter scale) manufacturing processes in an environment compliant with current Good Manufacturing Practices (cGMPs). We currently have more than 200 people dedicated to internal manufacturing activities in our 100,000 square-foot facility in Rensselaer, NY. Our manufacturing activities include production, quality control, quality assurance, process development and validation. The company has the capability to manufacture multiple product candidates simultaneously and expand production capacity for commercialization, which is essential to support the growing clinical development programs. Commercialization Strategy Regeneron is committed to ensuring that patients and their healthcare providers have optimal access to its products in the market place. Depending on the product and the indication, Regeneron may choose to commercialize products itself or work in conjunction with a larger pharmaceutical partner. Regeneron markets ARCALYST ® (rilonacept) in the U.S. by itself and has recently expanded the capabilities and experience of its commercial group to do so. In the VEGF Trap-Eye collaboration, Regeneron retains U.S. commercialization rights; the aflibercept collaboration and the monoclonal antibodies collaboration generally provide Regeneron with shared commercial rights. Facilities Regeneron employs over 850 employees at its two facilities. Regeneron’s corporate headquarters are located in Tarrytown, New York and a large-scale manufacturing facility is located near Albany in Rensselaer, New York. In December 2006, we signed a 15-year lease for 194,000 square-feet of space in two of three new buildings to be constructed adjacent to our current facility in Tarrytown. This world-class laboratory and office complex will become the new corporate headquarters and research and development facility for Regeneron. We expect to occupy the new office and lab space by mid-2009. Investor Contact Media Contact Laura Lindsay Investor Relations Corporate Communications 914.345.7640 914.345.7800 [email protected] [email protected]

Information about ARCALYST® (rilonacept) 1.877.REGN.777 (1.877.734.6777)